Dishman Pharma - 4QFY2013 Result Preview - Angel Broking

Dishman Pharmaceutical is expected to report a top-line growth of 2.2% to Rs. 358cr. The OPM is expected to contract by 60bp yoy to 22.9%. As a result, net profit is expected to decrease by 8.6% yoy to Rs. 28.6cr on back of contraction in OPM.

We maintain our buy with a target of 206.

Source : Equity Bulls

Keywords